EUCTR2010-023956-99-IT进行中（未招募）不适用
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate
BRISTOL-M.SQUIBB0 个研究点目标入组 677 人开始时间: 2012年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 677
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inadequate response to methotrexate • Must have been taking methotrexate for at least 3 months at a minimal weekly dose of 15 mg and stable dose for 4 weeks prior to randomization • ACR global function status class 1-3 • Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist • hsCRP >/= 0.8 mg/dL
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Previously received or currently receiving concomitant biologic therapy
研究者
相似试验
进行中（未招募）
不适用
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to MethotrexateRHEUMATOID ARTHRITIS,NOSMedDRA version: 14.0Level: LLTClassification code 10039076Term: Rheumatoid arthritis and other inflammatory polyarthropathiesSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023956-99-ESBristol-Myers Squibb International Corporation677
进行中（未招募）
不适用
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to MethotrexateRHEUMATOID ARTHRITIS,NOSMedDRA version: 17.1Level: LLTClassification code 10039076Term: Rheumatoid arthritis and other inflammatory polyarthropathiesSystem Organ Class: 100000004859EUCTR2010-023956-99-BEBristol-Myers Squibb International Corporation677
未知
2 期
Phase IIB Rheumatoid Arthritis Dose Ranging Study for Clazakizumab in Subjects Who Are Not Responding to MethotrexateRheumatoid ArthritisJPRN-jRCT2080221588Bristol-Myers K.K.406
进行中（未招募）
不适用
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to MethotrexateEUCTR2010-023956-99-HUBristol-Myers Squibb International Corporation677
进行中（未招募）
不适用
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to MethotrexateEUCTR2010-023956-99-NLBristol-Myers Squibb International Corporation677